Utilizing Laboratory Results to Identify Emergency Department Patients with Indications for HIV Pre-Exposure Prophylaxis

Abstract

People newly diagnosed with HIV often have previous contact with health care professionals, often on multiple occasions, including within emergency departments (EDs). Although EDs have become vital partners in routine screening and linkage to care for persons with HIV, ED engagement in HIV prevention efforts, to include HIV risk assessment and pre-exposure prophylaxis (PrEP) referral, are rare. In this study, we electronically queried the hospital electronic health record (EHR) for ED encounters in 2019 and 2020 for patients who screened negative for HIV (N = 26,914) to identify objective evidence of HIV acquisition risk due to recent sexual behavior (sexually transmitted infection screen positive for chlamydia, syphilis, gonorrhea, or trichomoniasis) or recent injection drug practices (urine drug screen positive for heroin, amphetamines, cocaine, or other opiates). In the reviewed period, we identified 1324 patients (4.92%) at sufficient risk to warrant PrEP referral (i.e., PrEP indications), including 304 (22.96%) due to sexual behavior and 1032 (77.95%) due to potential injection drug use. Notably, among adults with PrEP indications regardless of transmission risk group, persons who inject drugs (PWID) represented a significantly larger proportion within our ED cohort as compared with Centers for Disease Control and Prevention (CDC) estimates for the US population (77.95% vs. 6.34%, p < 0.0001). Among adults with PrEP indications due to sexual behavior specifically, women represented a significantly larger proportion within our ED cohort as compared with estimates for the US population (62.17% vs. 16.48%, p < 0.0001). Our results demonstrate that utilizing laboratory results within the EHR may be a simple low-resource option for identifying and engaging PrEP candidates, especially women and PWID.

Get full access to this article

View all access options for this article.

References

Centers for Disease Control and Prevention (CDC). Estimated HIV incidence and prevalence in the United States, 2015–2019. HIV Surveillance Supplemental Report; Vol. 26, No. 1, 2021. Available at: http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html (Last accessed March 10, 2022 ).

United States Census Bureau. Table 1. Annual Estimates of the Resident Population for the United States, Regions, States, and Puerto Rico: April 1, 2010 to July 1, 2019 (NST-EST2019-01). Available at: https://www.census.gov/data/tables/time-series/demo/popest/2010s-national-total.html (Last accessed March 10, 2022 ).

Centers for Disease Control and Prevention (CDC). Issue brief: HIV in the Southern United States. 2019. Available at: https://www.cdc.gov/hiv/pdf/policies/cdc-hiv-in-the-south-issue-brief.pdf (Last accessed March 10, 2022 ).

Fonner

, Dalglish

, Kennedy

, et al. Effectiveness and safety of oral HIV pre-exposure prophylaxis for all populations. AIDS, 2016; 30:1973–1983.

Choopanya

, Martin

, Suntharasamai

, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok tenofovir study): A randomized, double-blind, placebo-controlled phase 3 trial. Lancet, 2013; 381:2083–2290.

Martin

, Vanichseni

, Suntharasamai

, et al. Renal function of participants in the Bangkok tenofovir study—Thailand, 2005–2012. Clin Infect Dis, 2014; 59:716–724.

Centers for Disease Control and Prevention (CDC). Preexposure prophylaxis for the prevention of HIV infection in the United States—2021 Update: A clinical practice guideline. 2021. Available at: https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf (Last accessed March 10, 2022 ).

United States Health and Human Service. America's HIV Epidemic Analysis Dashboard (AHEAD). Available at: https://ahead.hiv.gov (Last accessed March 10, 2022 ).

Mounzer

, Fusco

, Hsu

, et al. Are we hitting the target? HIV pre-exposure prophylaxis from 2012 to 2020 in the OPERA Cohort. AIDS Patient Care STDS, 2021; 35:419–427.

10.

Kota

, Mansergh

, Stephenson

, et al. Sociodemographic characteristics of HIV pre-exposure prophylaxis use and reasons for nonuse among gay, bisexual, and other men who have sex with men from three US cities. AIDS Patient Care STDS, 2021; 35:158–166.

11.

Ezennia

, Geter

, Smith

. The PrEP care continuum and Black men who have sex with men: A scoping review of published data on awareness, uptake, adherence, and retention in PrEP care. AIDS Behav, 2019; 23:2654–2673.

12.

Hojilla

, Vlahov

, Crouch

, et al. HIV pre-exposure prophylaxis (PrEP) uptake and retention among men who have sex with men in a community-based sexual health clinic. AIDS Behav, 2018; 22:1096–1099.

13.

Owens

, Hubach

, Williams

, et al. Facilitators and barriers of pre-exposure prophylaxis (PrEP) uptake among rural men who have sex with men living in the Midwestern U.S. Arch Sex Behav, 2020; 49:2179–2191.

14.

Golub

, Gamarel

, Rendina

, et al. From efficacy to effectiveness: Facilitators and barriers to PrEP acceptability and motivations from adherence among MSM and transgender women in New York City. AIDS Patient Care STDS, 2013; 27:248–254.

15.

Gallagher

, Link

, Ramos

, et al. Self-perception of HIV risk and candidacy for pre-exposure prophylaxis among men who have sex with men testing for HIV at commercial sex venues in New York City. LGBT Health, 2014; 1:218–224.

16.

Sullivan

, Mena

, Elopre

, et al. Implementation strategies to increase PrEP uptake in the South. Curr HIV/AIDS Rep, 2019; 16:259–269.

17.

Sullivan

, Woodyatt

, Koski

, et al. A data visualization and dissemination resource to support HIV prevention and care at the local level: Analysis and uses of the AIDSVu public data resource. J Med Internet Res, 2020; 22:e23173.

18.

Jenkins

, Gardner

, Thrun

, et al. Risk-based human immunodeficiency virus (HIV) testing fails to detect the majority of HIV-infected persons in medical care settings. Sex Transm Dis, 2006; 33:329–333.

19.

Smith

, Chang

M-H

, Duffus

, et al. Missed opportunities to prescribe preexposure prophylaxis in South Carolina, 2013–2016. Clin Infect Dis, 2019; 68:37–42.

20.

Ridgway

, Friedman

, Bender

, et al. Evaluation of an electronic algorithm for identifying cisgender female pre-exposure prophylaxis candidates. AIDS Patient Care STDS, 2021; 35:5–8.

21.

Haukoos

, White

DAE

, Rowan

, et al. HIV risk and pre-exposure prophylaxis eligibility among emergency department patients. AIDS Patient Care STDS, 2021; 35:211–219.

22.

Faryar

, Ancona

, Braun

, et al. Estimated proportion of an urban academic emergency department patient population eligible for HIV preexposure prophylaxis. Am J Emerg Med, 2021; 48:198–202.

23.

Kulie

, Castel

, Zheng

, et al. Targeted screening for HIV pre-exposure prophylaxis eligibility in two emergency departments in Washington, DC. AIDS Patient Care STDS, 2020; 34:516–522.

24.

Ridgway

, Almirol

, Bender

, et al. Which patients in the emergency department should receive preexposure prophylaxis? Implementation of a predictive analytics approach. AIDS Patient Care STDS, 2018; 32:202–207.

25.

Stanley

, Lora

, Merjavy

, et al. HIV prevention and treatment: The evolving role of the emergency department. Ann Emerg Med, 2017; 70:562–572.e563.

26.

Centers for Disease Control and Prevention (CDC). A guide to taking a sexual history. Available at: https://www.cdc.gov/std/treatment/sexualhistory.pdf (Last accessed March 10, 2022 ).

27.

United States Prevention Services Task Force. Screening for unhealthy drug use: Clinician Summary of USPSTF Recommendation. 2020. Available at: https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/drug-use-illicit-screening (Last accessed March 10, 2022 ).

28.

McKinzie

Sexually transmitted diseases. In: Rosen's Emergency Medicine: Concepts and Clinical Practice. Walls R, Hockberger R, Gausche-Hill M (editors). Philadelphia, PA: Elsevier; 2018. pp. 1197–1208.

29.

Smith

, Van

and el

, Grey

. Estimates of adults with indications for HIV pre-exposure prophylaxis by jurisdiction, transmission risk group, and race/ethnicity, United States, 2015. Ann Epidemiol, 2018; 28:850–857.e859.

30.

Centers for Disease Control and Prevention (CDC). HIV and Women: PrEP Coverage. Available at: https://www.cdc.gov/hiv/group/gender/women/prep-coverage.html (Last accessed March 10, 2022 ).

31.

Garrison

, Haberer

. Pre-exposure prophylaxis uptake, adherence, and persistence: A narrative review of interventions in the U.S. Am J Prev Med, 2021; 61:S73–S86.

32.

Centers for Disease Control and Prevention (CDC). HIV infection risk, prevention, and testing behaviors among persons who inject drugs—National HIV Behavioral Surveillance: Injection drug use, 23 U.S. Cities,. 2018. HIV Surveillance Special Report 24, 2020. Available at: http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html (Last accessed March 10, 2022 ).